09:00 AM EST, 01/07/2025 (MT Newswires) -- Immuneering ( IMRX ) said Tuesday that new data from an ongoing phase 2a trial of its lead candidate IMM-1-104 in pancreatic cancer showed better overall response and disease control rates.

The updated results for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel showed pancreatic cancer patients achieved an overall response rate of 43% and a disease control rate of 86%, compared with benchmarks of 23% and 48%, respectively, according to Immuneering ( IMRX ) Chief Executive Ben Zeskind.

In another combination arm with modified Folfirinox, all evaluable patients experienced target lesion shrinkage, including a 100% reduction, the company said.

As a monotherapy in second-line patients, IMM-1-104 demonstrated a partial response with 67% reduction in target lesions, according to Immuneering ( IMRX ).

The drug was well-tolerated in both combination and monotherapy arms, the company said, adding it plans to expand the phase 2a trial in 2025 to include three new combination arms.

Shares of Immuneering ( IMRX ) surged past 91% in recent premarket activity Tuesday.